Japan
· Delayed Price · Currency is JPY Chugai Pharmaceutical Company Description
Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally.
It offers oncology products, such as Alecensa, Avastin, FoundationOne, Herceptin, Kadcyla, Perjeta, Polivy, Tecentriq, and Phesgo; Actemra for humanized anti-human IL-6 receptor monoclonal antibody; CellCept for immunosuppressant; Edirol, an osteoporosis agent; Enspryng, a pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody; Evrysdi for spinal muscular atrophy agent; Hemlibra, an anti-coagulation factor IXa/X humanized bispecific monoclonal antibody; Mircera, an erythropoiesis-stimulating agent; PiaSky, a pH-dependent binding humanized anti-complement (C5) monoclonal antibody; Ronapreve, an anti-SARS-CoV-2 monoclonal antibody; Tamiflu, an anti-influenza agent; and Vabysmo, an anti VEGF/anti Ang-2 bispecific antibody.
The company has strategic alliances and collaboration with Roche Group. The company was founded in 1925 and is headquartered in Chuo-ku, Japan.
Chugai Pharmaceutical Co., Ltd. operates as a subsidiary of Roche Holding Ltd.
| Country | Japan |
| Founded | 1925 |
| Industry | Drug Manufacturers - General |
| Sector | Healthcare |
| Employees | 7,604 |
| CEO | Osamu Okuda |
Contact Details
Address: Nihonbashi Mitsui Tower Chuo, 103-8324 Japan | |
| Phone | 81 3 3281 6611 |
| Website | chugai-pharm.co.jp |
Stock Details
| Ticker Symbol | 4519 |
| Exchange | Tokyo Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | JPY |
| ISIN Number | JP3519400000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Osamu Okuda | Chief Executive Officer |
| Iwaaki Taniguchi | Chief Financial Officer |
| Toshiya Sasai | Head of Investor Relations |